Biostax (BTAX) 10-K 2 Apr 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Apr. 02, 2018	Jun. 30, 2017
Document And Entity Information
Entity Registrant Name	Immune Therapeutics, Inc.
Entity Central Index Key	1,559,356
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 15,232,785
Entity Common Stock, Shares Outstanding		389,846,113
Trading Symbol	IMUN
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,017

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 14,718	$ 74,389
Inventories	178,098
Total current assets	192,816	74,389
Fixed Assets:
Computer equipment, net of accumulated depreciation of $8,714 and $7,888 respectively	2,529	1,850
Deposits	200	200
Total assets	195,545	76,439
Current Liabilities:
Accounts payable	2,319,932	1,818,605
Accrued liabilities	2,489,404	3,156,759
Notes payable, net of debt discount	4,820,063	4,225,419
Derivative liability	1,669,532
Total current liabilities	11,298,931	9,200,783
Total liabilities	11,298,931	9,200,783
Commitments and Contingencies (Note 10)
Stockholders’ Deficit:
Common stock - par value $0.0001; 500,000,000 shares authorized; 386,782,473 and 250,428,133 shares issued and outstanding respectively	38,679	25,043
Additional paid in capital	366,625,144	360,420,026
Stock issuances due	103,226	962,429
Prepaid services	(226,667)	(822,500)
Accumulated deficit	(373,035,183)	(365,718,976)
Deficit attributable to common stockholders	(6,494,801)	(5,133,978)
Non-controlling interest	(4,608,585)	(3,990,366)
Total stockholders’ deficit	(11,103,386)	(9,124,344)
Total liabilities and stockholders’ deficit	$ 195,545	$ 76,439

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Accumulated depreciation	$ 8,714	$ 7,888
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	386,782,473	250,428,133
Common stock, shares outstanding	386,782,473	250,428,133

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Revenues, net		$ 3,463
Operating expenses:
Selling, general and administrative	2,831,662	3,886,599
Research and development expense	399,443	444,165
Stock issued for services general and administrative	2,091,828	5,212,304
Warrant valuation	590,605	4,730,726
Depreciation and amortization expense	826	1,557
Total operating expenses	5,914,364	14,275,351
Loss from operations	(5,914,364)	(14,271,888)
Other expense:
Interest expense	(1,216,985)	(3,446,564)
Loss on valuation of derivative	(1,669,532)
Gain/(Loss) on settlement of debt	866,455	(2,100,549)
Total other expense	(2,020,062)	(5,547,113)
Net loss	(7,934,426)	(19,819,001)
Net loss attributable to non-controlling interest	(618,219)	(297,600)
Net loss attributable to common stockholders	$ (7,316,207)	$ (19,521,401)
Basic loss per share attributed to common stockholders	$ (0.02)	$ (0.09)
Weighted average number of shares outstanding	320,721,134	216,687,993

Consolidated Statements of Stoc

Consolidated Statements of Stockholders’ Equity/ (Deficit) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Stock to Be Issued [Member]	Prepaid Services [Member]	Accumulated Deficit [Member]	Non-Controlling Interest [Member]	Total
Balance at Dec. 31, 2015	$ 17,485	$ 343,434,786	$ 1,140,303	$ (660,417)	$ (347,789,889)	$ (2,100,452)	$ (5,958,184)
Balance, shares at Dec. 31, 2015	174,850,047
Issuance of common stock for prepaid services	$ 3,262	5,678,998	(307,875)	(3,072,535)			$ 2,301,850
Issuance of common stock for prepaid services, shares	32,633,910						32,633,910
Amortization of prepaid services				2,910,452			$ 2,910,452
Discount on warrants issued in connection with notes payable		682,665					682,665
Issuance of common stock for legal expenses	$ 15	22,485					22,500
Issuance of common stock for legal expenses, shares	150,000
Issuance of common stock for interest expense	$ 463	403,287					403,750
Issuance of common stock for interest expense, shares	4,621,296
Issuance of common stock in exchange for debt	$ 3,625	5,242,272	155,001				5,400,898
Issuance of common stock in exchange for debt, shares	36,235,380
Issuance of common stock for cash and exercise of warrants	$ 193	224,807	(25,000)				200,000
Issuance of common stock for cash and exercise of warrants, shares	1,937,500
Issuance and modification of common stock warrants		4,730,726					4,730,726
Issuance of stock of Cytocom					1,592,314	(1,592,314)
Net loss					(19,521,401)	(297,600)	(19,819,001)
Balance at Dec. 31, 2016	$ 25,043	360,420,026	962,429	(822,500)	(365,718,976)	(3,990,366)	(9,124,344)
Balance, shares at Dec. 31, 2016	250,428,133
Issuance of common stock for prepaid services	$ 2,900	2,352,299	(859,203)	(1,060,000)			$ 435,996
Issuance of common stock for prepaid services, shares	28,995,460						28,995,460
Amortization of prepaid services				1,655,833			$ 1,655,833
Issuance of common stock for interest expense	$ 815	393,747					394,562
Issuance of common stock for interest expense, shares	8,147,570
Issuance of common stock in exchange for debt	$ 4,499	2,167,350					2,171,849
Issuance of common stock in exchange for debt, shares	44,987,128
Issuance of common stock for cash and exercise of warrants	$ 5,422	701,117					706,539
Issuance of common stock for cash and exercise of warrants, shares	54,224,182
Issuance and modification of common stock warrants		590,605					590,605
Net loss							(7,934,426)
Balance at Dec. 31, 2017	$ 38,679	$ 366,625,144	$ 103,226	$ (226,667)	$ (373,035,183)	$ (4,608,585)	$ (11,103,386)
Balance, shares at Dec. 31, 2017	386,782,473

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss including non-controlling interest	$ (7,934,426)	$ (19,819,001)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation	826	1,557
Stock issued for services	435,995	2,324,350
Amortization of stock issued for prepaid services	1,655,833	2,910,452
Loss on derivative	1,669,532
(Gain)/Loss on settlement of debt and accounts payable	(866,455)	2,100,549
Stock warrant expense	590,605	4,730,726
Stock issued for loan expenses and interest	73,863	403,750
Amortization of debt discount	146,386	989,035
Expenses paid by lenders	31,361	115,202
Accounts receivable write off		2,661
Changes in operating assets and liabilities:
Accounts receivable		(13,536)
Inventory	(178,098)
Accrued liabilities	1,402,173	2,846,461
Accounts payable	919,141	540,983
Net cash used in operating activities	(2,053,263)	(2,839,739)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of computer equipment	(1,505)	(1,725)
Net cash used in investing activities	(1,505)	(1,725)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of common stock	706,539	200,000
Proceeds from notes payable	1,608,440	2,768,631
Repayment of notes payable	(319,882)	(75,927)
Net cash provided by financing activities	1,995,097	2,892,704
Increase/(decrease) in cash	(59,671)	51,240
Cash and cash equivalents, beginning of year	74,389	23,149
Cash and cash equivalents, end of year	14,718	74,389
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	43,000	29,567
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of notes payable, accrued liabilities and accounts payable to common stock	3,201,973	3,363,731
Accrued liabilities converted to note payable		388,143
Notes payable for expenses paid by lender		115,201
Debt discounts on notes payable	120,000	1,007,716
Transfer from accounts payable to notes payable	215,314
Cashless exercise of warrants	2,144
Non-cash additions to notes payable	114,343
Warrants issued for accounts payable	207,500
Shares issued for accrued interest expense	82,982
Loss on stock accrued to be issued for debt settlement	$ 110,035

Organization and Description of

Organization and Description of Business	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	1. Organization and Description of Business Immune Therapeutics, Inc. (the “Company,” “we,” or “our”) was initially incorporated in Florida on December 2, 1993 as Resort Clubs International, Inc. (“Resort Clubs”). It was formed to manage and market golf course properties in resort markets throughout the United States. Galliano International Ltd. (“Galliano”) was incorporated in Delaware on May 27, 1998 and began trading in November 1999 through the filing of a 15C-211. On November 10, 2004, Galliano merged with Resort Clubs. Resort Clubs was the surviving corporation. On August 23, 2010, Resort Clubs changed its name to pH Environmental Inc. (“pH Environmental”). On April 23, 2012, pH Environmental completed a name change to TNI BioTech, Inc., and on April 24, 2012, we executed a share exchange agreement for the acquisition of all of the outstanding shares of TNI BioTech IP, Inc. On September 4, 2014, a majority of our shareholders approved an amendment to our Amended and Restated Articles of Incorporation, as amended, to change our name to Immune Therapeutics, Inc. We filed our name change amendment with the Secretary of State of Florida on October 27, 2014 changing our name to Immune Therapeutics, Inc. The Company currently has an office in Orlando, Florida. In July 2012, the Company’s focus turned to acquiring patents that would protect and advance the development of new uses of opioid-related immune- therapies, such as low dose naltrexone (“LDN”) and Methionine [Met5]-enkephalin (“MENK”). In October 2012, the Company formed TNI BioTech International, Ltd., a BVI company in Tortola, British Virgin Islands, which was set up to allow the Company to market and sell LDN in those countries outside the U.S. in which we have been able to obtain approval to sell the Company’s products. In August 2013, the Company formed its United Kingdom subsidiary, TNI BioTech, LTD (the “UK Subsidiary”). The UK Subsidiary received approval to be considered a micro, small or medium-sized enterprise (“SME”) with the European Medicines Agency (“EMA”) on August 21, 2013. The designation provides the UK Subsidiary with significant discounts when holding meetings or submitting filings to the EMA. On September 19, 2013, the UK Subsidiary submitted a pre-submission package to the EMA regarding Crohn’s Disease. The EMA granted the UK Subsidiary a meeting that took place on September 27, 2013. The UK Subsidiary is eligible to benefit from the provisions for administrative and financial assistance for SMEs set out in Regulation (EC) No 2049/2005. The Company will apply to obtain EMA benefits once funding becomes available. In December 2013, the Company formed a subsidiary, Cytocom Inc., to focus on conducting LDN and MENK clinical trials in the United States. In December 2014, the Company finalized the distribution of common stock of Cytocom Inc. to its shareholders. As part of the transaction, the Company transferred to Cytocom certain of its rights, title and interest in or relating to intellectual property (i) patents, patent applications, and all divisional, continuations and continuations-in-part thereof, together with all reissues, reexaminations, renewals and extensions thereof and all rights to obtain such divisionals, continuations and continuations-in-part, reissues, reexaminations, renewals and extensions, and all utility models and statutory invention registrations and any other such analogous rights, (ii) trademarks, service marks, Internet domain names, trade dress, trade styles, logos, trade names, services names, brand names, corporate names, assumed business names and general intangibles and other source identifiers of a like nature, together with the goodwill associated with any of the foregoing, and all registrations and applications for registrations thereof, together with all renewals and extensions thereof and all rights to obtain such renewals and extensions, (iii) copyrights, mask work rights, database and design rights, moral rights and rights in Internet websites, whether registered or unregistered and whether published or unpublished, all registrations and recordings thereof and all applications in connection therewith, together with all renewals, continuations, reversions and extensions thereof and all rights to obtain such renewals, continuations, reversions and extensions, and (iv) confidential and proprietary information, including, trade secrets and know-how. Cytocom licensed back to the Company a perpetual, non-exclusive, royalty-free right and license to use the assigned intellectual property for veterinary indications and for the marketing rights to emerging markets, access to all clinical data, use of the formulation for LDN and MENK. The parties agreed that until such time as Cytocom was funded, the Company would be responsible for all payments to employees, ongoing general and administrative expenses, licensing fees, patent fees, and drug development costs. In March 2014, the Company incorporated Airmed Biopharma Limited, an Irish corporation with an address in Dublin, Ireland, and Airmed Holdings Limited, an Irish company domiciled in Bermuda. The Irish companies were set up to benefit from incentives granted by the Irish government for the establishment of pharmaceutical companies (many of the world’s leading pharmaceutical companies have located in Ireland), and so that the Company could take advantage of Ireland’s status as a member of the European Union and the European Economic Area. An Irish limited liability company enjoys a low corporate income tax rate of 12.5%, one of the lowest in the world. The Irish-domiciled company hopes to qualify for tax incentives for Irish holding/headquartered companies and to benefit from the network of double tax treaties that reduce withholding taxes. TNI BioTech International, Ltd. will manage our international distribution, using product that is manufactured in Ireland and elsewhere. We are focused on the development and commercialization of therapeutic treatments for cancer, HIV/AIDS and autoimmune diseases and immune disorders by combating these severe and fatal diseases through the stimulation and/or regulation of the body’s immune system. Our growth strategy includes the near-term commercialization of our existing immunotherapies targeting cancer, Crohn’s disease and/or HIV/AIDS. Going Concern The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through private equity financings. Management expects operating losses and negative cash flows to continue at more significant levels in the future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its product candidate and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings, and may seek additional capital through arrangements with strategic partners or from other sources. Based on the Company’s operating plan, existing working capital at December 31, 2017 was not sufficient to meet the cash requirements to fund planned operations through December 31, 2017 without additional sources of cash. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business. The Company experienced a net loss of $7,934,426 and used cash and cash equivalents for operations in the amount of $2,053,263 during the year ended December 31, 2017, and had a stockholders’ deficit of $11,103,386 at December 31, 2017.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The preparation of financial statements and related disclosures in conformity with U.S. generally accepted accounting principles (“GAAP”) and the Company’s discussion and analysis of its financial condition and operating results require the Company’s management to make judgments, assumptions, and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. Note 1, “Summary of Significant Accounting Policies” of the Notes to Consolidated Financial Statements in Part II, Item 8 of this Form 10-K describes the significant accounting policies and methods used in the preparation of the Company’s consolidated financial statements. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. We have identified the policies below as critical to our business operations and the understanding of its results of operations. The Company’s senior management has reviewed these critical accounting policies and related disclosures with the Company’s Board of Directors. The impact and any associated risks related to these policies on our business operations are discussed throughout this section where such policies affect our reported and expected financial results. Our preparation of financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of our financial statements, and the reported amounts of revenues and expenses during the reporting period. There can be no assurance that actual results will not differ from those estimates and such differences may be material. Revenue Recognition Revenue from product sales is recognized upon passage of title and risk of loss to customers. Provisions for discounts, rebates and sales incentives to customers, and returns and other adjustments are provided for in the period the related sales are recorded. Historical data are not yet readily available and reliable for use in estimating the amount of the reduction in gross sales. Revenue from the launch of a new product, from an improved version of an existing product, or for shipments in excess of a customer’s normal requirements will be recorded when the conditions noted above are met. In those situations, management will record a returns reserve for such revenue, if necessary. If in future the Company participates in selling arrangements that include multiple deliverables (e.g., instruments, reagents, procedures, and service agreements), under these arrangements, the Company will recognize revenue upon delivery of the product or performance of the service and will allocate the revenue based on the relative selling price of each deliverable, which will be based primarily on vendor specific objective evidence. Revenue from license of product rights is recorded over the periods earned. In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers, which provides a single comprehensive model for accounting for revenue from contracts with customers and will supersede most existing revenue recognition guidance. The standard becomes effective for the Company in the first quarter of 2018. The Company is currently evaluating the effect, if any, that the standard will have on its consolidated financial statements and related disclosures. Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates. Cash, Cash Equivalents, and Short-Term Investments The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000. At December 31, 2017, the Company has no cash balances in excess of insured limits. Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making. Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “ Financial Instruments” Derivative Financial Instruments FASB ASC 820, Fair Value Measurements Fair Value Measurements The ASC Topic 820, Fair Value Measurement, Inventory Inventories are stated at the lower of cost or market with cost based on the first-in, first-out (FIFO) method. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical trials or clinical manufacturing campaigns. Fixed Assets Fixed assets are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense for the years ended December 31, 2017 and December 31, 2016 was $826 and $1,557, respectively. Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or change in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360-10-05, “ Property, Plant and Equipment Research and Development Costs Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses. Income Taxes The Company follows ASC Topic 740, Income Taxes, The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of December 31, 2017 and 2016, the Company does not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of December 31, 2017, and 2016, the Company has not accrued any interest or penalties related to uncertain tax positions. Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The majority of the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, “ Equity-Based Payments to Non-Employees Non-controlling Interest In accordance with ASC Topic 810, Consolidation Net Loss per Share Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. A calculation of basic and diluted net loss per share follows: For the year ended December 31, 2017 2016 Historical net loss per share: Numerator Net loss $ (7,934,426 ) $ (19,819,001 ) Non-controlling interest (618,219 ) (297,600 ) Net loss attributed to common stockholders $ (7,316,207 ) $ (19,521,401 ) Denominator Weighted-average common shares outstanding— Denominator for basic and diluted net loss per share 320,720,134 216,687,993 Basic and diluted net loss per share attributed to common stockholders $ (0.02 ) $ (0.09 ) The Company’s potential dilutive securities which include stock and warrants have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average Common stock outstanding used to calculate both basic and diluted net loss per share is the same. The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive: Year Ended December 31, 2017 2016 Common Stock Purchase Warrants 84,287,402 59,191,904 Convertible Debt 81,880,906 _ Recent Accounting Standards During the year ended December 31, 2017 and through April 2, 2018, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. With the exception of ASC 606 — Revenue From Contracts With Customers The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2017, our last fiscal year. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.

Fixed Assets

Fixed Assets	12 Months Ended
	Dec. 31, 2017
Fixed Assets:
Fixed Assets	3. Fixed Assets December 31, 2017 2016 Fixed assets: Computer equipment $ 11,243 $ 9,738 Less accumulated depreciation (8,714 ) (7,888 ) Fixed assets, net $ 2,529 $ 1,850 The Company utilizes the straight-line method for depreciation, using three to five-year depreciable asset lives. Depreciation expense was not material for all periods presented.

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Accrued Liabilities	4. Accrued Liabilities Accrued expenses and other liabilities consist of the following: December 31, 2017 2016 Accrued payroll to officers and others 1,539,777 1,126,261 Accrued interest and penalties - notes payable 703,141 1,902,018 Estimated legal settlements 136,057 128,087 Other accrued liabilities 393 393 Estimated loss on note conversions 110,036 - Derivative Liability 1,669,532 - Total accrued expenses and other liabilities $ 4,158,936 $ 3,156,759

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Notes Payable	5. Notes Payable Notes payable consist of the following: December 31, 2017 December 31, 2016 Promissory note issued July 29, 2014 to Ira Gaines. In 2016, the maturity date on the note was extended to December 1, 2017. As of December 31, 2017 the note is in default. The note earns interest at a rate of 18% per annum. $ 100,000 $ 100,000 Promissory notes issued between November 26, 2014 and December 31, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. Notes aggregating $286,000 were in default at December 31, 2017, as the Company was unable to pay installments on those notes on their due dates. 286,000 286,000 Promissory notes issued between May 1, 2015 and December 31, 2016, and maturing between June 14, 2015 and December 1, 2017. Lenders on loans aggregating $505,994 earn interest at rates between 2% and 18% per annum. On loans aggregating $200,000, interest is payable in a fixed amount not tied to a specific interest rate. Notes aggregating $705,994 were in default at December 31, 2017, as the Company was unable to repay those notes on their due dates. 705,994 704,494 Promissory notes issued by Cytocom Inc. between April 29, 2015 and December 31, 2015. Lenders earn interest at rates between 5% and 10% per annum. These notes mature on December 31, 2016. At December 31, 2017, the notes were in default. 425,000 425,000 Promissory note issued in December 2015. The lender earns interest at a rate of 10% per month. The note is repayable on March 9, 2016. On April 3, 2017, the Company settled the obligation. - 100,000 Promissory notes issued between May 5, 2016 and June 2, 2016 that mature between October 1, 2016 and January 31, 2017, and include stock conversion features, warrants and original issue debt discounts. The notes were repaid or converted into stock in the quarter ended December 31, 2017. - 554,882 Promissory notes issued to an officer of the Company effective November 3, 2015 and maturing November 3, 2016 for settlement of accrued payroll, bearing interest at 10% per annum and including a stock conversion feature. The Company was unable to repay the note at maturity and the note is in default. 97,737 112,737 Promissory note issued in July 2016. The note was repayable on October 5, 2016 but was extended to December 31, 2016. The note earns interest at 6% per month. The Company was unable to repay the note at maturity and the note is in default. 50,000 50,000 Promissory note for $180,000 was issued in July 2016 with an original issue discount of $30,000. The note is repayable on April 7, 2017. The Company was unable to repay the note at maturity and the note is in default. Under the terms of the note, the principal amount was increased in 2017 to $243,000, and interest accrued at 25% per annum. $161,976 of principal and $20,025 of accrued interest were converted into 7,447,448 shares, of which 5,500,000 shares were issued at year end. The Company has accrued a $243,199 derivative liability for the $81,024 principal balance attributable to the conversion feature contained in this note. 81,024 180,000 Promissory notes issued in August 2016 for $149,854 as a settlement of amounts owed to a law firm. The notes accrue interest at 5% per annum and are payable in 18 equal monthly installments of $8,642. The note was in default on December 31, 2017. 17,284 120,987 Promissory notes issued between July 1, 2016 and December 31, 2016. Lenders earn interest at 2% per annum. The notes mature on December 31, 2017 and are in default. 206,000 256,000 Notes aggregating $1,354,000 issued in the fourth quarter of 2016. The notes accrue interest at 2% per annum and mature between November 1, 2017 and December 31, 2017. As of December 31, 2017the notes are in default. 1,354,000 1,354,000 Notes aggregating $500,000 issued in the first quarter of 2017. The notes accrue interest at 2% per annum and mature between January 12, 2018 and June 30, 2018. 500,000 - Promissory note issued January 25, 2017. The lenders earn interest at 7% per month. The note matures on July 5, 2017 and is in default. 50,000 - Notes aggregating $300,000 issued in the second quarter of 2017. The notes accrue interest at 2% per annum and mature between January 12, 2018 and June 30, 2018. 300,000 - Notes aggregating $191,800 issued in the third quarter of 2017. The notes accrue interest at 2% per annum and mature between June 16, 2018 and December 31, 2018. 191,800 - Promissory note for $425,000 was issued in October 2017 with an original issue discount of $70,000. The note is in default, giving the Holder an option to convert the note to stock. The Company has accrued a $1,426,333 derivative liability for the conversion right. 425,000 - Notes aggregating $108,500 issued in the fourth quarter of 2017. The notes accrue interest at 2% per annum and mature on December 31, 2018. 105,500 - Less: Original issue discounts on notes payable and warrants issued with notes. (75,277 ) (18,681 ) Total $ 4,820,062 $ 4,225,419 As of December 31, 2017, the Company had accrued $703,141 in unpaid interest and default penalties. During the year ended December 31, 2017, 8,147,570 shares with a fair value of $394,562 were issued by the Company for interest expense under promissory notes. As of December 31, 2016, the Company had accrued $399,271 in unpaid interest and $1,502,747 in default penalties. During the year ended December 31, 2016, 4,621,296 shares with a fair value of $403,750 were issued by the Company for interest expense under promissory notes.

Derivatives Liabilities

Derivatives Liabilities	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Derivatives Liabilities	6. DERIVATIVE LIABILITIES During the year ended December 31, 2017, notes payable aggregating $506,024 were issued as convertible debt or became convertible and qualified as a derivative liability under FASB ASC 815. As of December 31, 2017, and December 31, 2016, the aggregate fair value of the outstanding derivative liability was $1,669,532 and $0 respectively. The Company estimated the fair value of the derivative liability using the Black-Scholes option pricing model using the following key assumptions during the year ended December 31, 2017: Year End December 31, 2017 Volatility 247 % Risk-free interest rate 1.81 % Expected dividends -% Expected term 1.0 – 5 years The Company determines the fair market values of its financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The following three levels of inputs may be used to measure fair value: Level 1 Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company uses Level 3 inputs to estimate the fair value of its derivative liabilities. The following schedule summarizes the valuation of financial instruments at fair value in the balance sheets as of December 31, 2017: Fair Value Measurements as of December 31, 2017 Level 1 Level 2 Level 3 Assets None $ - $ - $ - Total assets - - - Liabilities Conversion option derivative liability - - 1,669,532 Total liabilities $ - $ - $ 1,669,532 The following table sets forth a reconciliation of changes in the fair value of derivative liabilities classified as Level 3 in the fair value hierarchy: Significant Unobservable Inputs (Level 3) Beginning balance $ - Change in fair value 1,669,532 Ending balance $ 1,669,532

Capital Structure - Common Stoc

Capital Structure - Common Stock and Common Stock Purchase Warrants	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Capital Structure - Common Stock and Common Stock Purchase Warrants	7. Capital Structure—Common Stock and Common Stock Purchase Warrants Each holder of common stock is entitled to vote on all matters and is entitled to one vote for each share held. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock or any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. As of December 31, 2017 and 2016, the Company was authorized to issue 500,000,000 common shares at a par value of $0.0001 per share. As of December 31, 2017, the Company had 386,782,473 shares of common stock outstanding and 250,428,133 outstanding as of December 31, 2016. Stock Warrants In 2017, the Company issued 66,789,711 warrants, exercisable into one share of common stock of the Company for each warrant at prices between $0.01 and $3.74 per share. The warrants expire between December 2019 and June 2032. When the Company sells its stock to stockholders for cash, it periodically issues warrants to those stockholders to acquire additional stock at prices agreed at the date of the original sale. The Company incurs a cost for the rights attached to the warrants, which is calculated using the Black-Scholes Model. This expense is reported in the Statements of Operations above as the Warrant valuation expense. For the years ended December 31, 2017, and December 31, 2016, the warrant valuation expense was $590,605 and $4,730,726 respectively. The Black-Scholes option pricing model used the following key assumptions during the year ended December 31, 2017: Year End December 31, 2017 Volatility 172 % - 247% Risk-free interest rate 1.46% - 1.81% Expected dividends -% Expected term 2.0 – 5 years During 2017, there were no modifications of the terms of any warrants issued by the Company. Following is a summary of outstanding stock warrants at December 31, 2017: Number of Shares Exercise Price Weighted Average Price Warrants as of December 31, 2015 9,131,500 $ 0.07-15 $ 1.47 Issued in 2016 50,222,904 $ 0.03-2.00 $ 0.16 Expired and forfeited in 2016 (162,500 ) $ 5.00 $ 5.00 Exercised in 2016 0 $ 0 $ 0 Warrants as of December 31, 2016 59,191,904 $ 0.03-15.00 $ 0.35 Issued in 2017 66,789,711 $ 0.01-3.74 $ 0.14 Expired and forfeited in 2017 11,053,762 $ 0.01-9.00 $ 0.13 Exercised in 2017 30,640,451 $ 0.01-0.20 $ 0.01 Warrants as of December 31, 2017 84,287,402 $ 0.01-15.00 $ 0.33 Summary of outstanding warrants as of December 31, 2017: Expiration Date Number of Shares Exercise Price Remaining Life (years) First Quarter 2018 127,500 $ 15.00 0.00 Second Quarter 2018 33,334 $ 15.00 0.25 Third Quarter 2018 250,000 $ 1.50 0.50 Fourth Quarter 2018 6,089,166 $ 1.00-1.50 0.75 First Quarter 2019 4,024,000 $ 0.50-2.00 1.00 Second Quarter 2019 135,000 $ 0.07-0.23 1.25 Third Quarter 2019 260,000 $ 0.50-1.50 1.50 Fourth Quarter 2019 10,620,272 $ 0.05-3.74 1.75 Second Quarter 2020 300,000 $ 0.50 2.25 Fourth Quarter 2020 1,000,000 $ 0.20 2.75 First Quarter 2021 12,600,000 $ 0.20 3.00 Second Quarter 2021 5,812,252 $ 0.01-0.20 3.25 Third Quarter 2021 5,016,667 $ 0.03-0.20 3.50 Second Quarter 2022 1,750,000 $ 0.15 4.25 Third Quarter 2022 2,650,000 $ 0.05-0.10 4.50 Fourth Quarter 2022 9,811,422 $ 0.08-0.29 4.75 Second Quarter 2023 2,000,000 $ 0.20 5.25 Second Quarter 2032 21,807,789 $ 0.01-0.07 14.25 84,287,402

Stock Compensation

Stock Compensation	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Compensation	8. Stock Compensation Shares Issued for Services During the years ended December 31, 2017 and 2016, the Company issued 28,995,460 and 32,633,910 shares of common stock respectively for consulting fees. The Company valued these shares based upon the fair value of the common stock at the dates of the agreements. The consulting fees are amortized over the contract periods which are typically between 12 and 24 months. The amortization of prepaid services totaled $2,091,828 and $2,910,452 for the years ended December 31, 2017 and 2016, respectively.

Income Taxes - Results of Opera

Income Taxes - Results of Operations	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes - Results of Operations	9. Income Taxes - Results of Operations There was no income tax expense reflected in the results of operations for the years ended December 31, 2017 and 2016 because the Company incurred a net loss in both years. On December 22, 2017, the President of the United States signed the Tax Cuts and Jobs Act (“U.S. Tax Reform”), which enacts a wide range of changes to the U.S. corporate income tax system. The impact of U.S. Tax Reform primarily represents the Company’s estimates of revaluing the Company’s U.S. deferred tax assets and liabilities based on the rates at which they are expected to be recognized in the future. For U.S. federal purposes the corporate statutory income tax rate was reduced from 35% to 21%, effective for the 2018 tax year. Based on the Company’s historical financial performance, at December 31, 2017, the net deferred tax asset position was remeasured at the lower corporate rate of 21% and a tax expense was recognized to adjust net deferred tax assets to the reduced value. Deferred tax assets: 2017 2016 Net operating losses $ 18,102,000 $ 27,153,000 Stock based compensation 39,054,000 63,108,000 Amortization, depreciation, and impairment 4,178,000 6,765,000 Capitalization of start-up costs for tax purposes 1,145,000 1,854,000 Loss on debt conversion of debt 569,000 1,216,000 Total deferred tax assets 63,048,000 99,382,000 Valuation allowance (63,048,000 ) (99,382,000 ) Total deferred tax assets, net $ - $ - The Company has recognized no tax benefit for the losses generated for the periods through December 31, 2017. ASC Topic 740 requires that a valuation allowance be provided if it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company’s ability to realize the benefit of its deferred tax asset will depend on the generation of future taxable income. Because the Company has yet to recognize revenue, we believe that the full valuation allowance should be provided. Our effective tax rate for fiscal years 2017 and 2016 was 0%. Our tax rate can be affected by recurring items, such as tax rates in foreign jurisdictions and the relative amount of income we earn in jurisdictions. It may also be affected by discrete items that may occur in any given year, but are not consistent from year to year. As of December 31, 2017, we have estimated federal and state income tax net operating loss (“NOL”) carry-forwards of approximately $86,000,000, which will expire in 2032-2037. 2017 2016 Amount Percent Amount Percent Benefits for income tax at federal statutory rate $ 1,666,000 34 % $ 6,738,000 34 % Change in valuation allowance 36,334,000 - $ (6,983,000 ) (34 ) Permanent differences - - (2,000 ) - Change in estimates (38,000,000 ) - 247,000 - $ - - % $ - - %

Licenses and Supply Agreements

Licenses and Supply Agreements	12 Months Ended
	Dec. 31, 2017
Licenses And Supply Agreements
Licenses and Supply Agreements	10. Licenses and Supply Agreements Patent and Subsidiary Acquisition The Company entered into a share exchange agreement on April 24, 2012 to acquire all of the outstanding shares of TNI BioTech IP, Inc. (“TNI IP”), a biotechnology firm incorporated in Florida and formed to acquire patents related to the treatment of cancer and HIV/AIDS and autoimmune diseases, using Met-enkephalin (“MENK”) and Naltrexone (“LDN”). The goal of TNI IP’s management was to enable mankind and civilization to combat fatal diseases by activating and mobilizing the body’s own immune system using TNI IP’s patented use of MENK. The first patents acquired by TNI IP were acquired from Dr. Nicholas P. Plotnikoff and Professor Fengping Shan in 2012. TNI IP was acquired in exchange for 20,250,000 shares of the Company’s common stock, of which 8,000,000 shares were issued to Dr. Plotnikoff for the acquisition of patents and the remaining 12,250,000 shares were issued to the founders of TNI IP in exchange for all of their right, title and interest in their TNI IP shares. The goodwill arising on the acquisition of TNI BioTech IP, Inc. was valued at $98,000,000 and license agreements arising from the acquisition of TNI IP were valued at $16,006,000. In connection with the share exchange, we entered into a Sale of Technology Agreement with Dr. Nicholas P. Plotnikoff on March 4, 2012, wherein Dr. Plotnikoff agreed to transfer and assign all of his rights, title and interest in: European Patent United Kingdom, Germany, France, Ireland EP 1401471 BI Methods for inducing sustained immune response; Russian Patent Russian Federation patent number 2313364; The Patent Office of the People’s Republic of China, Application No.: 200810165784.8 China Patent CN1015113407 A The Patent Office of the People’s Republic of China ISSN: 1006-2858 CN 21-1349/R; Patent Agencies Government of India Patent, Application number 1627/KOLNP/2003 number 220265 an Enkephalin Peptide Composition; and the US Patent Pending, US Patent Application 10/146.999 e. The Company received all the production formulations and technology designs from Dr. Plotnikoff necessary for the manufacturing, formulation, production and protocols of the MENK treatment of cancer and HIV/AIDS. As consideration for entering into the Sale of Technology Agreement, Dr. Plotnikoff received 8,000,000 shares of common stock, a royalty of a single-digit percentage on all sales of MENK and was granted the position of Non-Executive Chairman of the Board of Directors. At the time of the acquisition, the valuation of goodwill and other intangible assets were determined using the fair market price for the Company’s common stock, which were exchanged for shares of TNI IP. In the fourth quarter of 2012, the Company performed an annual valuation to determine whether any goodwill or intangible assets that had been acquired by the Company were impaired. The result of this valuation was that material impairments were identified. The Company recognized an impairment of the goodwill arising on the acquisition of TNI IP of $98,000,000. Patent License Agreements On August 13, 2012, the Company signed an exclusive License Agreement with Ms. Jacqueline Young (the “Young Agreement”) for the intellectual property developed by Dr. Bernard Bihari relating to treatments with opioid antagonists such as naltrexone and Met-enkephalin for a variety of diseases and conditions including malignant lymphoma, chronic lymphocytic leukemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma, chronic herpes virus infections, chronic herpes viral infections such as chronic genital herpes caused by the herpes simplex virus Type 2 and chronic infections due to the Epstein-Barr virus and a treatment method for humans infected with HTLV-III (AIDS) virus, including patients clinically diagnosed as suffering from AIDS and those suffering from AIDS-related complex (ARC). The Bihari patents were acquired in exchange for 540,000 shares of the Company’s common stock with a fair value of $972,000 and assumed liabilities of $400,000, which is payable to Ms. Young over a twenty-four month period in equal installments to reimburse her for the costs of a New York City office in accordance with the Young Agreement. The cost of the patent totaled $1,372,000. Additionally, the Company will pay the licensor a royalty payment of 1% of gross MENK sales and provide the licensor a position as non-executive chairman of the Company. The Young Agreement is valid for the life of the patents and expires on a country by country basis in each country where patent rights exist, upon the expiration of the last to expire patent in each country or in the event the patent in such country is held to be invalid and/or unenforceable (by a court or government body of competent jurisdiction) or admitted to be invalid or unenforceable. Additionally, we can cancel the Young Agreement upon 120 days’ written notice and shall pay all royalties and fees that have accrued under the Young Agreement. We have the exclusive rights to the intellectual property; however, Ms. Young retains a right to practice the patents licensed under the Young Agreement solely for noncommercial, academic research purposes. On December 24, 2012, the Company signed an agreement for the acquisition of patent rights (the “Smith Agreement”) for the intellectual property of Dr. Jill Smith and LDN Research Group, LLC (collectively, the “Licensor Parties”), whose members are Dr. Ian S. Zagon, Dr. Patricia J. McLaughlin and Moshe Rogosnitzky and orphan drug designation by the FDA to a novel late-stage drug, trademarked “LDN,” for the treatment of Pediatric Crohn’s disease. The patent covers methods and formulations for treatment of the inflammatory and ulcerative diseases of the bowel, using naltrexone in low doses as an opioid antagonist. These patents were acquired in exchange for 300,000 shares of our common stock with a fair value of $2,715,000 and payment of $165,384 (consisting of a $100,000 initial license fee and payment of $65,384 of expenses), which totaled $2,880,384. The Smith Agreement requires the Company to (i) use commercially reasonable efforts to develop, commercialize, market and sell licensed products in a manner consistent with a business plan, (ii) expend a minimum amount of funds per annum to develop and commercialize licensed products as soon as practicable, (iii) obtain all requisite regulatory approvals needed to use or sell licensed products in the field of use, and (iv) make the first commercial sale of a licensed product by March of 2017. The Company is required to pay an annual license fee, an annual running royalty on net sales of each licensed product or a minimum royalty, whichever is greater, and a sublicense fee on payments received by the Company from sublicensees. The Company has an exclusive, worldwide license to make, have made, use, lease, import, offer for sale and sell licensed products and to use the method under the patent rights. The Smith Agreement will terminate on the expiration or abandonment of the last patent to expire or ten years after the sale of the first licensed product. The Company may terminate the Smith Agreement upon 90 days’ written notice, provided all sublicenses are terminated and all amounts due and owing are paid to the Licensor Parties. The Licensor Parties may terminate the agreement ten days’ after notice to the Company if the Company is ten days late in payment or there is a breach that remains uncured for ten days after written notice of such breach. The Company is also required to pay milestone payments after substantial achievement of certain milestone events for each licensed product including payment: upon initiation of each Phase III trial; upon positive completion of each Phase III clinical trial of the therapeutic use of an LDN compound in the field of use; when a New Drug Application (“NDA”) is accepted for review by the FDA; and when FDA approval to market the NDA is approved. The Company will issue shares upon reaching certain milestones including upon the first dosing of the first patient in a Phase III clinical trial for each licensed product, upon the first sale of each licensed product, and upon the achievement of a set dollar amount in cumulative sales for each licensed product covered by NDAs. As part of the Smith Agreement, the Company has the right to apply to the FDA for the transfer of the orphan drug status for the use of naltrexone for the treatment of pediatric Crohn’s disease and ulcerative colitis, the Investigation New Drug Application (“IND”), and the right to acquire the relevant clinical data set from Dr. Jill Smith. Dr. Jill Smith made arrangements to transfer the IND to the Company as well as the relevant clinical data set, and the FDA has acknowledged that the Company is now the sponsor for this IND. On September 24, 2014, the Company and the Licensor Parties jointly agreed to terminate the Smith Agreement, and in place thereof, have the Licensor Parties grant a similar license in their patent rights to Cytocom Inc. pursuant to a Patent License Agreement between the Licensor Parties, Cytocom Inc. and the Company with substantially similar terms as set forth in the Smith Agreement. Pursuant to this agreement, the Company issued 1,000,000 shares of its common stock valued at $270,000, upon execution to the Licensor Parties and the Company guaranteed the obligations of Cytocom Inc. to the Licensor Parties under the agreement. On January 18, 2013, the Company signed an exclusive licensing agreement with The Penn State Research Foundation to license all of the intellectual property developed by Dr. Ian S. Zagon, Dr. Patricia J. McLaughlin and Dr. Jill P. Smith for the treatment of cancer titled “Opioid Growth Factor and Cancer” and “Combination Therapy with Opioid Growth Factor and Taxanes for the Treatment of Cancer” (the “Foundation Agreement”). The Foundation Agreement requires the Company to: (a) use commercially reasonable efforts to develop, commercialize, market and sell licensed products in a manner consistent with a business plan; (b) expend a minimum amount of funds per annum to develop and commercialize licensed products as soon as practicable; (c) obtain all requisite regulatory approvals needed to use or sell licensed products in the field of use; and (d) make the first commercial sale of a licensed product by December 31, 2016. The Foundation Agreement provides that the Company must pay to the licensor an initial license fee, a license maintenance fee on each anniversary of the effective date of the Foundation Agreement, and an annual running royalty on net sales for each licensed product or a minimum royalty, whichever is greater. In addition, the Company must pay a sublicense fee on payments received by the Company from sublicensees. The Foundation Agreement also requires the Company to make payments upon the achievement of certain milestone events including: initiation of each Phase II trial; initiation of each Phase III trial; when the NDA is accepted for review by the FDA; and when FDA approval to market is approved. The Company must also issue shares upon certain milestones including upon the first dosing of the first patient in a Phase II clinical trial for each licensed product, upon the first dosing of the first patient in a Phase III clinical trial for each licensed product, upon the first sale of each licensed product, and upon the achievement of a set dollar amount of cumulative sales for each licensed product covered by NDAs. The Foundation Agreement terminates on the expiration or abandonment of the last patent to expire or become abandoned. The Company may terminate the Foundation Agreement at any time upon 60 days’ prior written notice and ceasing to make and sell all licensed products, the termination of all sublicenses and payment of all monies owed under the Foundation Agreement. The licensor may terminate the agreement 30 days after notice to the Company if the Company is 30 days late in payment or a breach that remains uncured for 45 days after written notice of such breach. In May of 2013, the Company executed a Patent License Agreement with Professor Fengping Shan (the “Shan Agreement”) pursuant to which it obtained exclusive rights to develop and commercialize the licensed technology. The licensed technology is the intellectual property developed and owned by Professor Shan (i) relating to the treatment of a variety of diseases and conditions with MENK including multiple forms of lymphoma and cancer and (ii) a treatment method for humans infected with the HLTV-III (AIDS) virus including AIDS and AIDS related complex (ARC). The licensed technology includes the methods and formulations for these treatments including all INDs, communications with regulatory agencies, patient data, and letters relating to these treatments. The licensed technology also includes certain patents developed by Professor Shan. Under the Shan Agreement, the Company must issue 500,000 shares to Professor Shan upon final transfer of the licenses, and reimburse Professor Shan for all out of pocket expenses in connection with the patents. The Company will pay Professor Shan a running royalty on gross sales subject to decreases if third party intellectual property is needed to complete such sale or product. The Shan Agreement lasts for the duration of each of the licensed patents however the Company may terminate the Shan Agreement on 120 days’ written notice to Professor Shan. On August 6, 2014, Professor Fengping Shan executed an Assignment pursuant to which he transferred to the Company his entire right, title and interest in and to the licensed patents under the Shan Agreement and CN 201210302259 Application of combination of low-dose naltrexone and methionine-enkephalin to preparation of anti-cancer drug for the consideration of 500,000 shares of common stock valued at $140,000.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies Malawi Treatment Facilities On July 14, 2012, GB Oncology and Imaging Group LTD (“GBOIG”) in partnership with the Company signed a letter of intent agreement to collaborate with the Government of Malawi to assist in expanding the treatment of cancer, HIV/AIDS and other infectious diseases. In December of 2014, the Government of Malawi completed an oncology clinic at the Queen Elizabeth Central Hospital in Blantyre, Malawi for the treatment of cancer and infectious diseases. In 2015, the Company submitted protocols seeking permission from the Pharmacy, Medicines and Poisons Board of Malawi (“PMPB”) to conduct two trials involving Lodonal™ in Malawi: a. The first protocol, submitted jointly with The Jack Brewer Foundation (“JBF Worldwide”), received PMPB approval on November 11, 2015. The protocol covers a 12-month trial for a “Single Visit Approach to Cervical Cancer Prevention.” The approach is designed to deliver a preventive and simple procedure that can be performed in a clinical setting without the use of a laboratory and to allow for immediate treatment of any precancerous lesions utilizing Wallach LL100 Cryosurgical systems. The protocol provides for 50% of the patient group to be put on Lodonal™ to determine if the drug lowers the number of opportunistic infections during the year, and if it can be shown that LDN increases CD4, CE8, NK and T cell count, which would show that the incidence rates of opportunistic infection could decrease with Lodonal™ and that Lodonal™ could be used as a prophylaxis to prevent substantial HIV-related morbidity in Malawi. The PMPB approved the trial in late 2016 and recruitment began in late 2016 and continued through first quarter of 2018, with the trial now ongoing. b. The second protocol, which has not yet been approved, covers a trial using Lodonal™ for the treatment of cancer. The Company has put this trial on hold as it may not be necessary with the approval in Nigeria in addition to the pending approval in Kenya and Senegal for Lodonal™ for the treatment of cancer. Distribution Agreements in Nigeria Effective November 9, 2012, we signed an exclusive Distribution Agreement with G-Ex Technologies/St. Maris Pharma and GB Pharma Holdings, LLC for the Federal Republic of Nigeria. The parties have been unable to perform under the agreement because a certificate of free sale was not obtained by the Company until November of 2013, and no extension has been granted. In October 2013, the Company announced the signing of a Distribution Agreement with AHAR Pharma, a Nigerian company, to market Lodonal™, in Nigeria for the treatment of autoimmune diseases and cancer. AHAR intends to distribute Lodonal™ through a local distributor network, an Internet client base and directly to hospitals, pharmacists and doctors in Nigeria. The first deliveries under the agreement took place in February 2018. Under the original agreement, the Company is obligated to provide delivery of an initial supply of between 1 million and 1.5 million doses of Lodonal™ product to cover AHAR Pharma’s first-year purchase commitment. These commitments are currently under review by the parties. In August 2015, the Company announced the signing of a letter of intent with GB Pharma/AHAR and Fidson Healthcare Plc., in terms of which Fidson will promote Lodonal TM TM Agreements with Hubei Qianjiang Pharmaceutical Company On October 18, 2012, the Company and Hubei Qianjiang Pharmaceutical Co., Ltd. (“Qianjiang Pharmaceutical”), signed a Venture Cooperation Agreement on New Drug Methionine Enkephalin (the “Venture Agreement”) pursuant to which Qianjiang Pharmaceutical acquired an exclusive license for the production of MENK in China. The Venture Agreement requires that Qianjiang Pharmaceutical conduct drug research and pilot testing for MENK, organize pre-clinical studies, and apply for clinical trials for MENK with the Chinese State Food and Drug Administration. Under the Venture Agreement, Qianjiang Pharmaceutical must open a co-administration account for the development of MENK in China. Qianjiang Pharmaceutical must pay the Company, upon the marketing of MENK products, a half-year amount equaling 6% of its gross sales from MENK of the preceding half year. The Company may cancel the Venture Agreement if Qianjiang Pharmaceutical does not pay expenses for a period exceeding six months or does not commence clinical trials within 12-months after receiving certain approvals. Qianjiang Pharmaceutical may cancel the Venture Agreement if the Company fails to perform its obligations for a period of six months or the failure to receive approval of clinical trials is due to the Company’s MENK technologies. The Venture Agreement was amended on February 24, 2013 to expand the clinical trials from pancreatic to both pancreatic and liver cancer and amended on March 6, 2014 to require Qianjiang Pharmaceutical to commence studies and clinical trials in China and place funds in the co-administration account. On August 6, 2014, the Company entered into a Supplementary Agreement on New Drug Methionine – Enkephalin Cooperation (the “Amendment”) with Qianjiang Pharmaceutical, amending the Venture Agreement, as amended. The Company and Qianjiang Pharmaceutical executed the Amendment to accelerate clinical trials in both the United States and China, and agreed to immediately initiate three month Good Laboratory Practice (“GLP”) Toxicology Studies (rat and dog) within 30 days of signing the Amendment. The Amendment requires that the GLP Toxicology Studies Trials are conducted in China in accordance with international standards and standards acceptable to the FDA and that the studies include the following: Exploratory Toxicology (nGLP) ● Dose range finding studies ● Different species and methods of administration ● Multiple dosing regimens ● Estimate the response vs. dose given Definitive Toxicology (GLP) ● Performed in collaboration with Calvert Laboratories (USA) and MPI/Medicillon (China) ● General toxicology studies ● Different species and methods of administration ● Immunogenicity study with NHPs Special Toxicology Studies (planned) Pursuant to the Amendment, Qianjiang Pharmaceutical has made certain funds available from the co-administrative account opened by Qianjiang Pharmaceutical under the Venture Agreement, in accordance with an approved budget and timeline set forth in the Amendment. A portion of these funds are expected to be used by Cytocom to run PK and Dosing trials for MENK in the United States in 2018. The Amendment requires Cytocom and Qianjiang Pharmaceutical to meet with the China State Food and Drug Administration to determine that PK and Dosing Trials completed in the United States will be acceptable. All developments and trials run by Cytocom in the U.S. or the European Union will be used for requesting registration approval in China. In February 2013, the Company signed a Strategic Framework Agreement for Cooperation with Qianjiang Pharmaceutical. Under the agreement, the parties will work together to further the development of new products and conduct research and development on the Company’s licensed patented technology. Specifically, the parties aim to co-invest to develop and market products focusing on HIV, cancer and related autoimmune system therapies, develop co-ventured manufacturing facilities in China, and develop co-ventured distribution of the developed products in China and Africa. The agreement does not have a definitive term, as each new agreement resulting from the cooperation will set forth the material terms, including, but not limited to, fees, duration and termination therein. In December of 2016 Qianjiang Pharmaceutical completed the following documents: Exploratory Toxicology (nGLP) ● Dose range finding studies ● Different species and methods of administration ● Multiple dosing regimens ● Estimate the response vs. dose given Definitive Toxicology (GLP) ● Performed in collaboration with Calvert Laboratories (USA) and MPI/Medicillon (China) ● General toxicology studies ● Different species and methods of administration ● Immunogenicity study with NHPs In addition to the pharmacology and toxicology studies, Qianjiang Pharmaceutical and China Peptide completed the formulation and CMC necessary to scale up manufacturing of MENK. Contract Manufacturing Agreements On May 16, 2016, the Company entered into an agreement with Complete Pharmacy and Medical Solutions, LLC (“CPMS”) to compound, package and distribute the LDN tablets, capsules and/or creams in the United States. The initial term of the agreement is three years, with the option to renew for an additional year. The agreement may be terminated by (i) mutual agreement, (ii) in the event of a breach, provided however that if the Company terminates the agreement, the Company will be required to reimburse CPMS for all unused packaging materials for the LDN, which unused packaging materials CPMS will provide to IMUN. If CPMS does not receive and ship at least 1,000 orders (prescriptions) during the term of the agreement, the Company will be required to reimburse CPMS for 100% of the “ramp up costs” (defined as all costs and expenses of labor and materials related to the testing, and required FDA and other governmental documentation/approvals of test data) of providing and producing the LDN, even where the Company cancels/terminates the agreement, which provision shall survive the cancellation/termination of the agreement. On October 25, 2016, the Company and Acromax Dominicana, SA ("Acromax"), which is based in the Dominican Republic, entered into a contract for manufacturing of LDN tablets, capsules and/or creams ("Agreement"). Subject to the terms and conditions of the Agreement, Acromax will obtain all necessary licenses and permits to carry out the manufacturing and packaging of LDN in exchange for a fixed fee per tablet plus an additional fee for packaging, shipping and customs clearance. The Agreement has an initial term of five years unless terminated by either party in accordance with the terms. Operating Leases At December 31, 2017, the Company was a party to agreements to lease office space in Orlando, Florida. Rental expense for the years ended December 31, 2017 and 2016 was $16,777 and $16,041 respectively. Legal Proceedings In November 11, 2016, the Company was sued by Kacem Enterprises, Inc. for $21,777 plus interest, costs and attorneys’ fees for travel related expenses incurred by certain consultants of the Company. On July 21, 2017, judgement was awarded against the Company in this amount. The Company has accrued $24,923 for these claims. In October, 2017, the Company was served with a lawsuit by Cote Orphan LLC, alleging failure by the Company to pay $36,000 for services performed by Cote Orphan for the Company. The Company’s defense is that the services were not fully performed, and that it therefore not obligated to pay. As of the date of this Form 10-K, settlement negotiations have taken place but no agreement has been reached by the parties. The Company has made no accrual for this claim.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	12. Related Party Transactions Robert Wilson, the son of Noreen Griffin, the Company’s Chief Executive Officer, is employed by the Company. In the year ended December 31, 2017, the Company paid compensation to Mr. Wilson totaling $100,000. In 2017, Mr. Wilson received 500,000 stock options, valued at $24,998. Kelly O’Brien Wilson, the daughter-in-law of Noreen Griffin, the Company’s Chief Executive Officer, is employed by the Company. In the year ended December 31, 2017, the Company paid compensation to Ms. Wilson totaling $136,158. In 2017, Ms. Wilson received 1,200,000 stock options, valued at $59,995. In 2017, the Company borrowed $373,000 under various notes payable from Robert J. Dailey, with an interest rate of 2% per annum. In 2017, the Company borrowed $30,000 under various notes payable from Paul Akin, with an interest rate of 2% per annum.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events On March 31, 2018, Mr. Paul Akin resigned his position as a director of the Company. Mr. Akin’s resignation did not result from a disagreement with the Company or the Board of Directors on any matter relating to its operations, policies or practices, including its controls or financial related matters. Between January 1, 2018 and April 2, 2018, the Company issued shares as follows: Number of Shares Issuance of common stock to employees and consultants 2,862,640 Issuance of common stock as incentive to extend a debt 200,000 As of April 2, 2018, the Company had outstanding 389,846,113 shares of common stock. Between January 1, 2018 and April 2, 2018, the Company issued 1,000,000 warrants for services and employment, exercisable into one share of common stock of the Company for each warrant at a price of $0.20 per share. The warrants expire in 5 years. Between January 1, 2018 and April 2, 2018, the Company borrowed $356,000. Terms of the loans are being negotiated. Between January 1, 2018 and April 2, 2018, Cytocom raised $125,000 through the issuance of common stock. The selling price of the stock is being negotiated.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The preparation of financial statements and related disclosures in conformity with U.S. generally accepted accounting principles (“GAAP”) and the Company’s discussion and analysis of its financial condition and operating results require the Company’s management to make judgments, assumptions, and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. Note 1, “Summary of Significant Accounting Policies” of the Notes to Consolidated Financial Statements in Part II, Item 8 of this Form 10-K describes the significant accounting policies and methods used in the preparation of the Company’s consolidated financial statements. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. We have identified the policies below as critical to our business operations and the understanding of its results of operations. The Company’s senior management has reviewed these critical accounting policies and related disclosures with the Company’s Board of Directors. The impact and any associated risks related to these policies on our business operations are discussed throughout this section where such policies affect our reported and expected financial results. Our preparation of financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of our financial statements, and the reported amounts of revenues and expenses during the reporting period. There can be no assurance that actual results will not differ from those estimates and such differences may be material.
Revenue Recognition	Revenue Recognition Revenue from product sales is recognized upon passage of title and risk of loss to customers. Provisions for discounts, rebates and sales incentives to customers, and returns and other adjustments are provided for in the period the related sales are recorded. Historical data are not yet readily available and reliable for use in estimating the amount of the reduction in gross sales. Revenue from the launch of a new product, from an improved version of an existing product, or for shipments in excess of a customer’s normal requirements will be recorded when the conditions noted above are met. In those situations, management will record a returns reserve for such revenue, if necessary. If in future the Company participates in selling arrangements that include multiple deliverables (e.g., instruments, reagents, procedures, and service agreements), under these arrangements, the Company will recognize revenue upon delivery of the product or performance of the service and will allocate the revenue based on the relative selling price of each deliverable, which will be based primarily on vendor specific objective evidence. Revenue from license of product rights is recorded over the periods earned. In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers, which provides a single comprehensive model for accounting for revenue from contracts with customers and will supersede most existing revenue recognition guidance. The standard becomes effective for the Company in the first quarter of 2018. The Company is currently evaluating the effect, if any, that the standard will have on its consolidated financial statements and related disclosures.
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.
Cash, Cash Equivalents, and Short-Term Investments	Cash, Cash Equivalents, and Short-Term Investments The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000. At December 31, 2017, the Company has no cash balances in excess of insured limits.
Segment and Geographic Information	Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making.
Fair Value of Financial Instruments	Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “ Financial Instruments”
Derivative Financial Instruments	Derivative Financial Instruments FASB ASC 820, Fair Value Measurements
Fair Value Measurements	Fair Value Measurements The ASC Topic 820, Fair Value Measurement,
Inventory	Inventory Inventories are stated at the lower of cost or market with cost based on the first-in, first-out (FIFO) method. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical trials or clinical manufacturing campaigns.
Fixed Assets	Fixed Assets Fixed assets are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense for the years ended December 31, 2017 and December 31, 2016 was $826 and $1,557, respectively.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or change in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360-10-05, “ Property, Plant and Equipment
Research and Development Costs	Research and Development Costs Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses.
Income Taxes	Income Taxes The Company follows ASC Topic 740, Income Taxes, The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of December 31, 2017 and 2016, the Company does not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of December 31, 2017, and 2016, the Company has not accrued any interest or penalties related to uncertain tax positions.
Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration	Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The majority of the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, “ Equity-Based Payments to Non-Employees
Non-controlling Interest	Non-controlling Interest In accordance with ASC Topic 810, Consolidation
Net Loss Per Share	Net Loss per Share Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. A calculation of basic and diluted net loss per share follows: For the year ended December 31, 2017 2016 Historical net loss per share: Numerator Net loss $ (7,934,426 ) $ (19,819,001 ) Non-controlling interest (618,219 ) (297,600 ) Net loss attributed to common stockholders $ (7,316,207 ) $ (19,521,401 ) Denominator Weighted-average common shares outstanding— Denominator for basic and diluted net loss per share 320,720,134 216,687,993 Basic and diluted net loss per share attributed to common stockholders $ (0.02 ) $ (0.09 ) The Company’s potential dilutive securities which include stock and warrants have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average Common stock outstanding used to calculate both basic and diluted net loss per share is the same. The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive: Year Ended December 31, 2017 2016 Common Stock Purchase Warrants 84,287,402 59,191,904 Convertible Debt 81,880,906 _
Recent Accounting Standards	Recent Accounting Standards During the year ended December 31, 2017 and through April 2, 2018, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. With the exception of ASC 606 — Revenue From Contracts With Customers The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2017, our last fiscal year. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Schedule of Basic and Diluted Net Loss Per Share	A calculation of basic and diluted net loss per share follows: For the year ended December 31, 2017 2016 Historical net loss per share: Numerator Net loss $ (7,934,426 ) $ (19,819,001 ) Non-controlling interest (618,219 ) (297,600 ) Net loss attributed to common stockholders $ (7,316,207 ) $ (19,521,401 ) Denominator Weighted-average common shares outstanding— Denominator for basic and diluted net loss per share 320,720,134 216,687,993 Basic and diluted net loss per share attributed to common stockholders $ (0.02 ) $ (0.09 )
Schedule of Antidilutive Securities	The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive: Year Ended December 31, 2017 2016 Common Stock Purchase Warrants 84,287,402 59,191,904 Convertible Debt 81,880,906 _

Fixed Assets (Tables)

Fixed Assets (Tables)	12 Months Ended
	Dec. 31, 2017
Fixed Assets:
Schedule of Fixed Assets	December 31, 2017 2016 Fixed assets: Computer equipment $ 11,243 $ 9,738 Less accumulated depreciation (8,714 ) (7,888 ) Fixed assets, net $ 2,529 $ 1,850

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued expenses and other liabilities consist of the following: December 31, 2017 2016 Accrued payroll to officers and others 1,539,777 1,126,261 Accrued interest and penalties - notes payable 703,141 1,902,018 Estimated legal settlements 136,057 128,087 Other accrued liabilities 393 393 Estimated loss on note conversions 110,036 - Derivative Liability 1,669,532 - Total accrued expenses and other liabilities $ 4,158,936 $ 3,156,759

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Schedule of Notes Payable	Notes payable consist of the following: December 31, 2017 December 31, 2016 Promissory note issued July 29, 2014 to Ira Gaines. In 2016, the maturity date on the note was extended to December 1, 2017. As of December 31, 2017 the note is in default. The note earns interest at a rate of 18% per annum. $ 100,000 $ 100,000 Promissory notes issued between November 26, 2014 and December 31, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. Notes aggregating $286,000 were in default at December 31, 2017, as the Company was unable to pay installments on those notes on their due dates. 286,000 286,000 Promissory notes issued between May 1, 2015 and December 31, 2016, and maturing between June 14, 2015 and December 1, 2017. Lenders on loans aggregating $505,994 earn interest at rates between 2% and 18% per annum. On loans aggregating $200,000, interest is payable in a fixed amount not tied to a specific interest rate. Notes aggregating $705,994 were in default at December 31, 2017, as the Company was unable to repay those notes on their due dates. 705,994 704,494 Promissory notes issued by Cytocom Inc. between April 29, 2015 and December 31, 2015. Lenders earn interest at rates between 5% and 10% per annum. These notes mature on December 31, 2016. At December 31, 2017, the notes were in default. 425,000 425,000 Promissory note issued in December 2015. The lender earns interest at a rate of 10% per month. The note is repayable on March 9, 2016. On April 3, 2017, the Company settled the obligation. - 100,000 Promissory notes issued between May 5, 2016 and June 2, 2016 that mature between October 1, 2016 and January 31, 2017, and include stock conversion features, warrants and original issue debt discounts. The notes were repaid or converted into stock in the quarter ended December 31, 2017. - 554,882 Promissory notes issued to an officer of the Company effective November 3, 2015 and maturing November 3, 2016 for settlement of accrued payroll, bearing interest at 10% per annum and including a stock conversion feature. The Company was unable to repay the note at maturity and the note is in default. 97,737 112,737 Promissory note issued in July 2016. The note was repayable on October 5, 2016 but was extended to December 31, 2016. The note earns interest at 6% per month. The Company was unable to repay the note at maturity and the note is in default. 50,000 50,000 Promissory note for $180,000 was issued in July 2016 with an original issue discount of $30,000. The note is repayable on April 7, 2017. The Company was unable to repay the note at maturity and the note is in default. Under the terms of the note, the principal amount was increased in 2017 to $243,000, and interest accrued at 25% per annum. $161,976 of principal and $20,025 of accrued interest were converted into 7,447,448 shares, of which 5,500,000 shares were issued at year end. The Company has accrued a $243,199 derivative liability for the $81,024 principal balance attributable to the conversion feature contained in this note. 81,024 180,000 Promissory notes issued in August 2016 for $149,854 as a settlement of amounts owed to a law firm. The notes accrue interest at 5% per annum and are payable in 18 equal monthly installments of $8,642. The note was in default on December 31, 2017. 17,284 120,987 Promissory notes issued between July 1, 2016 and December 31, 2016. Lenders earn interest at 2% per annum. The notes mature on December 31, 2017 and are in default. 206,000 256,000 Notes aggregating $1,354,000 issued in the fourth quarter of 2016. The notes accrue interest at 2% per annum and mature between November 1, 2017 and December 31, 2017. As of December 31, 2017the notes are in default. 1,354,000 1,354,000 Notes aggregating $500,000 issued in the first quarter of 2017. The notes accrue interest at 2% per annum and mature between January 12, 2018 and June 30, 2018. 500,000 - Promissory note issued January 25, 2017. The lenders earn interest at 7% per month. The note matures on July 5, 2017 and is in default. 50,000 - Notes aggregating $300,000 issued in the second quarter of 2017. The notes accrue interest at 2% per annum and mature between January 12, 2018 and June 30, 2018. 300,000 - Notes aggregating $191,800 issued in the third quarter of 2017. The notes accrue interest at 2% per annum and mature between June 16, 2018 and December 31, 2018. 191,800 - Promissory note for $425,000 was issued in October 2017 with an original issue discount of $70,000. The note is in default, giving the Holder an option to convert the note to stock. The Company has accrued a $1,426,333 derivative liability for the conversion right. 425,000 - Notes aggregating $108,500 issued in the fourth quarter of 2017. The notes accrue interest at 2% per annum and mature on December 31, 2018. 105,500 - Less: Original issue discounts on notes payable and warrants issued with notes. (75,277 ) (18,681 ) Total $ 4,820,062 $ 4,225,419

Derivatives Liabilities (Tables

Derivatives Liabilities (Tables)	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Schedule of Estimated Fair Value of the Derivative Liability	The Company estimated the fair value of the derivative liability using the Black-Scholes option pricing model using the following key assumptions during the year ended December 31, 2017: Year End December 31, 2017 Volatility 247 % Risk-free interest rate 1.81 % Expected dividends -% Expected term 1.0 – 5 years
Schedule of Valuation of Financial Instruments	The following schedule summarizes the valuation of financial instruments at fair value in the balance sheets as of December 31, 2017: Fair Value Measurements as of December 31, 2017 Level 1 Level 2 Level 3 Assets None $ - $ - $ - Total assets - - - Liabilities Conversion option derivative liability - - 1,669,532 Total liabilities $ - $ - $ 1,669,532
Schedule of Reconciliation of Changes in the Fair Value of Derivative Liabilities	The following table sets forth a reconciliation of changes in the fair value of derivative liabilities classified as Level 3 in the fair value hierarchy: Significant Unobservable Inputs (Level 3) Beginning balance $ - Change in fair value 1,669,532 Ending balance $ 1,669,532

Capital Structure - Common St26

Capital Structure - Common Stock and Common Stock Purchase Warrants (Tables)	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Schedule of Fair Value Assumptions of Stock Warrants	The Black-Scholes option pricing model used the following key assumptions during the year ended December 31, 2017: Year End December 31, 2017 Volatility xxx % - xxx% Risk-free interest rate 0.xx% - 1.xx% Expected dividends -% Expected term 0.xx – xx years
Schedule of Outstanding Stock Warrants	Following is a summary of outstanding stock warrants at December 31, 2017: Number of Shares Exercise Price Weighted Average Price Warrants as of December 31, 2016 59,191,904 $ 0.03-15.00 $ 0.35 Issued in 2017 66,789,711 $ 0.01-3.74 $ 0.14 Expired and forfeited in 2017 11,053,762 $ 0.01-9.00 $ 0.13 Exercised in 2017 30,640,451 $ 0.01-0.20 $ 0.01 Warrants as of December 31, 2017 84,287,402 $ 0.01-15.00 $ 0.33
Summary of Outstanding Warrants	Summary of outstanding warrants as of December 31, 2017: Expiration Date Number of Shares Exercise Price Remaining Life (years) First Quarter 2018 127,500 $ 15.00 0.00 Second Quarter 2018 33,334 $ 15.00 0.25 Third Quarter 2018 250,000 $ 1.50 0.50 Fourth Quarter 2018 6,089,166 $ 1.00-1.50 0.75 First Quarter 2019 4,024,000 $ 0.50-2.00 1.00 Second Quarter 2019 135,000 $ 0.07-0.23 1.25 Third Quarter 2019 260,000 $ 0.50-1.50 1.50 Fourth Quarter 2019 10,620,272 $ 0.05-3.74 1.75 Second Quarter 2020 300,000 $ 0.50 2.25 Fourth Quarter 2020 1,000,000 $ 0.20 2.75 First Quarter 2021 12,600,000 $ 0.20 3.00 Second Quarter 2021 5,812,252 $ 0.01-0.20 3.25 Third Quarter 2021 5,016,667 $ 0.03-0.20 3.50 Second Quarter 2022 1,750,000 $ 0.15 4.25 Third Quarter 2022 2,650,000 $ 0.05-0.10 4.50 Fourth Quarter 2022 9,811,422 $ 0.08-0.29 4.75 Second Quarter 2023 2,000,000 $ 0.20 5.25 Second Quarter 2032 21,807,789 $ 0.01-0.07 14.25

Income Taxes - Results of Ope27

Income Taxes - Results of Operations (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets	Deferred tax assets: 2017 2016 Net operating losses $ xxx $ 27,153,000 Stock based compensation xxx 63,108,000 Amortization, depreciation, and impairment xxx 6,765,000 Capitalization of start-up costs for tax purposes xxx 1,854,000 Loss on debt conversion of debt xxx 1,216,000 Total deferred tax assets 99,382,000 Valuation allowance xxx ) (99,382,000 ) Total deferred tax assets, net $ - $ -
Schedule of Income Taxes NOL	2017 2016 Amount Percent Amount Percent Benefits for income tax at federal statutory rate $ xxx xxx % $ 6,738,000 34 % Change in valuation allowance xxx xxx )% $ (6,983,000 ) (34 ) Permanent differences xxx ) xxx (2,000 ) - Change in estimates xxx xxx 247,000 - $ - xxx % $ - - %

Subsequent Events (Tables)

Subsequent Events (Tables)	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Summary of Issued Shares	Between January 1, 2018 and April 2, 2018, the Company issued shares as follows: Number of Shares Issuance of common stock to employees and consultants 2,862,640 Issuance of common stock as incentive to extend a debt 200,000

Organization and Description 29

Organization and Description of Business (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	Apr. 30, 2017	Mar. 31, 2014	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Net loss			$ 7,934,426	$ 19,819,001
Cash and cash equivalents used in operating activities			2,053,263	2,839,739
Stockholder's deficit			$ 11,103,386	$ 9,124,344	$ 5,958,184
Cytocom Inc., [Member]
Reserve stock split description	The Board of Directors and a majority of shareholders of Cytocom approved a reverse stock split of Cytocom’s outstanding common stock with one new share of stock for each twenty old shares of common stock.
Irish Limited Liability [Member]
Percentage of low corporate income tax rate		12.50%

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Details Narrative)	12 Months Ended
	Dec. 31, 2017USD ($)Segment	Dec. 31, 2016USD ($)
Federal deposit insurance corporation value	$ 250,000
Number of operating segment | Segment	1
Depreciation expense	$ 826	$ 1,557
Accrued interest or penalties related to uncertain tax positions
Maximum of annual gross revenue	$ 1,000,000,000
Minimum [Member]
Property and equipment useful lives	3 years
Maximum [Member]
Property and equipment useful lives	5 years
Property and Equipment [Member] | Minimum [Member]
Property and equipment useful lives	3 years
Property and Equipment [Member] | Maximum [Member]
Property and equipment useful lives	5 years

Summary of Significant Accoun31

Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Numerator, Net loss	$ (7,934,426)	$ (19,819,001)
Numerator, Non-controlling interest	(618,219)	(297,600)
Numerator, Net loss attributed to Common stockholders	$ (7,316,207)	$ (19,521,401)
Weighted-average common shares outstanding Denominator for basic and diluted net loss per share	320,721,134	216,687,993
Basic and diluted net loss per share attributed to common stockholders	$ (0.02)	$ (0.09)

Summary of Significant Accoun32

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Convertible Debt [Member]
Potentially dilutive securities	81,880,906
Warrants To Purchase Common Stock [Member]
Potentially dilutive securities	84,287,402	59,191,904

Fixed Assets (Details Narrative

Fixed Assets (Details Narrative)	12 Months Ended
	Dec. 31, 2017
Minimum [Member]
Depreciable asset lives	3 years
Maximum [Member]
Depreciable asset lives	5 years

Fixed Assets - Schedule of Fixe

Fixed Assets - Schedule of Fixed Assets (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Fixed Assets:
Computer equipment	$ 11,243	$ 9,738
Less accumulated depreciation	(8,714)	(7,888)
Fixed assets, net	$ 2,529	$ 1,850

Accrued Liabilities - Schedule

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Accrued payroll to officers and others	$ 1,539,777	$ 1,126,261
Accrued interest and penalties - notes payable	703,141	1,902,018
Estimated legal settlements	136,057	128,087
Other accrued liabilities	393	393
Estimated loss on note conversions	110,036
Derivative Liability	1,669,532
Total accrued expenses and other liabilities	$ 2,489,404	$ 3,156,759

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Accrued unpaid interest and default penalties	$ 703,141
Issuance of common stock for settlement of promissory notes, shares	8,147,570	4,621,296
Issuance of common stock for settlement of promissory notes	$ 394,562	$ 403,750
Accrued unpaid interest		399,271
Accrued default penalties		$ 1,502,747

Notes Payable - Schedule of Not

Notes Payable - Schedule of Notes Payable (Details) - USD ($)	Dec. 31, 2017	Oct. 31, 2017	Dec. 31, 2016	Jul. 31, 2016
Total	$ 4,820,063		$ 4,225,419
Less: Original issue discounts on notes payable and warrants issued with notes	(75,277)		(18,681)
Notes Payable One [Member]
Total	100,000		100,000
Notes Payable Two [Member]
Total	286,000		286,000
Notes Payable Three [Member]
Total	705,994		704,494
Notes Payable Four [Member]
Total	425,000		425,000
Notes Payable Five [Member]
Total			100,000
Notes Payable Six [Member]
Total			554,882
Notes Payable Seven [Member]
Total	97,737		112,737
Notes Payable Eight [Member]
Total	50,000		50,000
Notes Payable Nine [Member]
Total	81,024		180,000
Less: Original issue discounts on notes payable and warrants issued with notes				$ 30,000
Notes Payable Ten [Member]
Total	17,284		120,987
Notes Payable Eleven [Member]
Total	206,000		256,000
Notes Payable Twelve [Member]
Total	1,354,000		1,354,000
Notes Payable Thirteen [Member]
Total	500,000
Notes Payable Fourteen [Member]
Total	50,000
Notes Payable Fifteen [Member]
Total	300,000
Notes Payable Sixteen [Member]
Total	191,800
Notes Payable Seventeen [Member]
Total	425,000
Less: Original issue discounts on notes payable and warrants issued with notes		$ 70,000
Notes Payable Eighteen [Member]
Total	$ 105,500

Notes Payable - Schedule of N38

Notes Payable - Schedule of Notes Payable (Details) (Parenthetical)	Jan. 25, 2017	Aug. 31, 2016USD ($)Installments	Jul. 31, 2016USD ($)	Jun. 02, 2016	Nov. 03, 2015	Jul. 29, 2014	Dec. 31, 2017USD ($)	Sep. 30, 2017USD ($)	Jun. 30, 2017USD ($)	Mar. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2017USD ($)shares	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)Doses	Dec. 31, 2016USD ($)	Oct. 31, 2017USD ($)
Accrued interest							$ 703,141				$ 1,902,018		$ 703,141	$ 1,902,018		$ 1,902,018
Original issuance discount							(75,277)				(18,681)		(75,277)	(18,681)		(18,681)
Derivative liability							$ 1,669,532				$ 0		1,669,532	0		$ 0
Proceeds from issuance of debt													$ 1,608,440	$ 2,768,631
Notes Payable Two [Member]
Percentage of interest rate per annum												10.00%			10.00%
Number of installments, months | Doses															36
Notes Payable Two [Member] | Maximum [Member]
Maximum amount raise in debt												$ 2,000,000			$ 2,000,000
Notes Payable Four [Member] | Cytocom Inc., [Member]
Note matures date												Dec. 31, 2016
Notes Payable Four [Member] | Maximum [Member] | Cytocom Inc., [Member]
Percentage of interest rate per annum												10.00%			10.00%
Notes Payable Four [Member] | Minimum [Member] | Cytocom Inc., [Member]
Percentage of interest rate per annum												5.00%			5.00%
Notes Payable Six [Member]
Debt instrument maturity date description				October 1, 2016 and January 31, 2017
Notes Payable Seven [Member]
Note matures date					Nov. 3, 2016
Percentage of interest rate per annum					10.00%
Notes Payable Eight [Member]
Percentage of interest rate per annum			6.00%
Notes Payable Nine [Member]
Note matures date			Apr. 7, 2017
Percentage of interest rate per annum							25.00%						25.00%
Maximum amount raise in debt			$ 180,000				$ 161,976						$ 161,976
Accrued interest							20,025						$ 20,025
Original issuance discount			$ 30,000
Number of note converted into common stock | shares													7,447,448
Number of shares issued | shares													5,500,000
Derivative liability							243,199						$ 243,199
Principal balance attributable to the conversion feature													81,024
Notes Payable Nine [Member] | Maximum [Member]
Maximum amount raise in debt							$ 243,000						$ 243,000
Notes Payable Ten [Member]
Percentage of interest rate per annum		5.00%
Maximum amount raise in debt		$ 149,854
Number of installments, months | Installments		18
Debt instrument, periodic payment, principal		$ 8,642
Notes Payable Eleven [Member] | Lenders [Member]
Note matures date														Dec. 31, 2017
Percentage of interest rate per annum											2.00%			2.00%		2.00%
Notes Payable Twelve [Member]
Percentage of interest rate per annum											2.00%			2.00%		2.00%
Notes aggregating default amount											$ 1,354,000			$ 1,354,000		$ 1,354,000
Debt instrument maturity date description											November 1, 2017 and December 31, 2017
Notes Payable Thirteen [Member]
Percentage of interest rate per annum										2.00%
Maximum amount raise in debt										$ 500,000
Debt instrument maturity date description										January 12, 2018 and June 30, 2018
Notes Payable Fifteen [Member]
Percentage of interest rate per annum									2.00%
Notes aggregating default amount									$ 300,000
Debt instrument maturity date description									January 12, 2018 and June 30, 2018
Notes Payable Sixteen [Member]
Percentage of interest rate per annum								2.00%
Notes aggregating default amount								$ 191,800
Debt instrument maturity date description								June 16, 2018 and December 31, 2018
Notes Payable Seventeen [Member]
Maximum amount raise in debt																	$ 425,000
Original issuance discount																	70,000
Derivative liability																	$ 1,426,333
Notes Payable Eighteen [Member]
Note matures date							Dec. 31, 2018
Percentage of interest rate per annum							2.00%						2.00%
Maximum amount raise in debt							$ 108,500						$ 108,500
Ira Gaines [Member] | Notes Payable One [Member]
Note matures date						Dec. 1, 2017
Percentage of interest rate per annum						18.00%
Lenders [Member] | Notes Payable Two [Member]
Notes aggregating default amount							286,000						286,000
Lenders [Member] | Notes Payable Three [Member]
Notes aggregating default amount							$ 705,994						$ 705,994
Aggregating loan											$ 505,994			505,994		505,994
Accrued interest											$ 200,000			$ 200,000		$ 200,000
Debt instrument maturity date description																June 14, 2015 and December 1, 2017
Lenders [Member] | Notes Payable Three [Member] | Maximum [Member]
Percentage of interest rate per annum											18.00%			18.00%		18.00%
Lenders [Member] | Notes Payable Three [Member] | Minimum [Member]
Percentage of interest rate per annum											2.00%			2.00%		2.00%
Lenders [Member] | Notes Payable Fourteen [Member]
Note matures date	Jul. 5, 2017
Percentage of interest rate per annum	7.00%
Lender [Member] | Notes Payable Five [Member]
Percentage of interest rate per annum												10.00%			10.00%

Derivatives Liabilities (Detail

Derivatives Liabilities (Details Narrative) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Notes to Financial Statements
Convertible debt	$ 506,024
Fair value of derivative liabilities	$ 1,669,532	$ 0

Derivatives Liabilities - Sched

Derivatives Liabilities - Schedule of Estimated Fair Value of the Derivative Liability (Details)	12 Months Ended
	Dec. 31, 2017
Volatility	247.00%
Risk-free interest rate	1.81%
Expected dividends	0.00%
Minimum [Member]
Expected term	1 year
Maximum [Member]
Expected term	5 years

Derivatives Liabilities - Sch41

Derivatives Liabilities - Schedule of Valuation of Financial Instruments (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Total assets	$ 195,545	$ 76,439
Conversion option derivative liability	1,669,532	0
Total liabilities	11,298,931	9,200,783
Level 1 [Member]
Total assets
Conversion option derivative liability
Total liabilities
Level 2 [Member]
Total assets
Conversion option derivative liability
Total liabilities
Level 3 [Member]
Total assets
Conversion option derivative liability	1,669,532
Total liabilities	$ 1,669,532

Derivatives Liabilities - Sch42

Derivatives Liabilities - Schedule of Reconciliation of Changes in the Fair Value of Derivative Liabilities (Details)	12 Months Ended
	Dec. 31, 2017USD ($)
Derivative liabilities beginning balance	$ 0
Derivative liabilities ending balance	1,669,532
Unobservable Inputs Level 3 [Member]
Derivative liabilities beginning balance
Change in fair value	1,669,532
Derivative liabilities ending balance	$ 1,669,532

Capital Structure - Common St43

Capital Structure - Common Stock and Common Stock Purchase Warrants (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Common stock, shares authorized	500,000,000	500,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares issued	386,782,473	250,428,133
Common stock, shares outstanding	386,782,473	250,428,133
Number of warrants issued during period	66,789,711
Warrant expire term	expire between December 2019 and June 2032
warrant valuation expense	$ 590,605	$ 4,730,726
Minimum [Member]
Warrant price per share	$ 0.01
Maximum [Member]
Warrant price per share	$ 3.74

Capital Structure - Schedule of

Capital Structure - Schedule of Fair Value Assumptions of Stock Warrants (Details) - Warrant [Member]	12 Months Ended
	Dec. 31, 2017
Expected dividends	0.00%
Minimum [Member]
Volatility	172.00%
Risk-free interest rate	1.46%
Expected term	2 years
Maximum [Member]
Volatility	247.00%
Risk-free interest rate	1.81%
Expected term	5 years

Capital Structure - Common St45

Capital Structure - Common Stock and Common Stock Purchase Warrants - Schedule of Outstanding Stock Warrants (Details) - Warrant [Member] - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Number of Shares Warrants, Beginning balance	59,191,904	9,131,500
Number of Shares Warrants, Issued	66,789,711	50,222,904
Number of Shares Warrants, Expired and forfeited	11,053,762	(162,500)
Number of Shares Warrants, Exercised	30,640,451	0
Number of Shares Warrants, Ending balance	84,287,402	59,191,904
Exercise Price, Expired and forfeited		$ 5
Exercise Price, Exercised		0
Weighted average exercise price, Beginning balance	$ 0.35	1.47
Weighted average exercise price, Issued	0.14	0.16
Weighted average exercise price, Expired and forfeited	0.13	5
Weighted average exercise price, Exercised	0.01	0
Weighted average exercise price, Ending balance	0.33	0.35
Minimum [Member]
Exercise Price, Beginning balance	0.03	0.07
Exercise Price, Issued	0.01	0.03
Exercise Price, Expired and forfeited	0.01
Exercise Price, Exercised	0.01
Exercise Price, Ending balance	0.01	0.03
Maximum [Member]
Exercise Price, Beginning balance	15
Exercise Price, Issued	3.74
Exercise Price, Expired and forfeited	9
Exercise Price, Exercised	0.20
Exercise Price, Ending balance	$ 15	$ 15

Capital Structure - Common St46

Capital Structure - Common Stock and Common Stock Purchase Warrants - Summary of Outstanding Warrants (Details)	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Number of Shares | shares	84,287,402
First Quarter 2018 [Member]
Number of Shares | shares	127,500
Exercise Price Upper Limit	$ 15
Remaining Life (years)	0 years
Second Quarter 2018 [Member]
Number of Shares | shares	33,334
Exercise Price Upper Limit	$ 15
Remaining Life (years)	2 months 30 days
Third Quarter 2018 [Member]
Number of Shares | shares	250,000
Exercise Price Upper Limit	$ 1.50
Remaining Life (years)	6 months
Fourth Quarter 2018 [Member]
Number of Shares | shares	6,089,166
Exercise Price Lower Limit	$ 1
Exercise Price Upper Limit	$ 1.50
Remaining Life (years)	9 months
First Quarter 2019 [Member]
Number of Shares | shares	4,024,000
Exercise Price Lower Limit	$ 0.50
Exercise Price Upper Limit	$ 2
Remaining Life (years)	1 year
Second Quarter 2019 [Member]
Number of Shares | shares	135,000
Exercise Price Lower Limit	$ 0.07
Exercise Price Upper Limit	$ 0.23
Remaining Life (years)	1 year 2 months 30 days
Third Quarter 2019 [Member]
Number of Shares | shares	260,000
Exercise Price Lower Limit	$ 0.50
Exercise Price Upper Limit	$ 1.50
Remaining Life (years)	1 year 6 months
Fourth Quarter 2019 [Member]
Number of Shares | shares	10,620,272
Exercise Price Lower Limit	$ 0.05
Exercise Price Upper Limit	$ 3.74
Remaining Life (years)	1 year 9 months
Second Quarter 2020 [Member]
Number of Shares | shares	300,000
Exercise Price Upper Limit	$ 0.50
Remaining Life (years)	2 years 2 months 30 days
Fourth Quarter 2020 [Member]
Number of Shares | shares	1,000,000
Exercise Price Upper Limit	$ 0.20
Remaining Life (years)	2 years 9 months
First Quarter 2021 [Member]
Number of Shares | shares	12,600,000
Exercise Price Upper Limit	$ 0.20
Remaining Life (years)	3 years
Second Quarter 2021 [Member]
Number of Shares | shares	5,812,252
Exercise Price Lower Limit	$ 0.01
Exercise Price Upper Limit	$ 0.20
Remaining Life (years)	3 years 2 months 30 days
Third Quarter 2021 [Member]
Number of Shares | shares	5,016,667
Exercise Price Lower Limit	$ 0.03
Exercise Price Upper Limit	$ 0.20
Remaining Life (years)	3 years 6 months
Second Quarter 2022 [Member]
Number of Shares | shares	1,750,000
Exercise Price Upper Limit	$ 0.15
Remaining Life (years)	4 years 2 months 30 days
Third Quarter 2022 [Member]
Number of Shares | shares	2,650,000
Exercise Price Lower Limit	$ 0.05
Exercise Price Upper Limit	$ 0.10
Remaining Life (years)	4 years 6 months
Fourth Quarter 2022 [Member]
Number of Shares | shares	9,811,422
Exercise Price Lower Limit	$ 0.08
Exercise Price Upper Limit	$ 0.29
Remaining Life (years)	4 years 9 months
Second Quarter 2023 [Member]
Number of Shares | shares	2,000,000
Exercise Price Upper Limit	$ 0.20
Remaining Life (years)	5 years 2 months 30 days
Second Quarter 2032 [Member]
Number of Shares | shares	21,807,789
Exercise Price Lower Limit	$ 0.01
Exercise Price Upper Limit	$ 0.07
Remaining Life (years)	14 years 2 months 30 days

Stock Compensation (Details Nar

Stock Compensation (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Number of common stock issued for consulting fees	28,995,460	32,633,910
Amortization of prepaid services	$ 2,091,828	$ 2,910,452
Minimum [Member]
Consulting fees amortized period	12 months
Maximum [Member]
Consulting fees amortized period	24 months

Income Taxes - Results of Ope48

Income Taxes - Results of Operations (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income tax examination, description	The impact of U.S. Tax Reform primarily represents the Company’s estimates of revaluing the Company’s U.S. deferred tax assets and liabilities based on the rates at which they are expected to be recognized in the future. For U.S. federal purposes the corporate statutory income tax rate was reduced from 35% to 21%,
Lower corporate tax rate	21.00%
Effective tax rate	0.00%	0.00%
Operating loss carryforwards	$ 86,000,000
Operating loss carryforwards expire term	expire in 2032-2037

Income Taxes - Results of Ope49

Income Taxes - Results of Operations - Schedule of Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Net operating losses	$ 18,102,000	$ 27,153,000
Stock based compensation	39,054,000	63,108,000
Amortization, depreciation, and impairment	4,178,000	6,765,000
Capitalization of start-up costs for tax purposes	1,145,000	1,854,000
Loss on debt conversion of debt	569,000	1,216,000
Total deferred tax assets	63,048,000	99,382,000
Valuation allowance	(63,048,000)	(99,382,000)
Total deferred tax assets, net

Income Taxes - Results of Ope50

Income Taxes - Results of Operations - Schedule of Income Taxes NOL (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Benefits for income tax at federal statutory rate	$ 1,666,000	$ 6,738,000
Change in valuation allowance	36,334,000	(6,983,000)
Permanent differences		(2,000)
Change in estimates	(38,000,000)	247,000
Net operating loss
Benefits for income tax at federal statutory rate, percent	34.00%	34.00%
Change in valuation allowance, percent	0.00%	(34.00%)
Permanent differences, percent	0.00%	0.00%
Change in estimates, percent	0.00%	0.00%
Effective income tax rate reconciliation, percent	0.00%	0.00%

Licenses and Supply Agreements

Licenses and Supply Agreements (Details Narrative) - USD ($)	Sep. 24, 2014	Aug. 06, 2014	Dec. 24, 2012	Aug. 13, 2012	Apr. 24, 2012	May 31, 2013	Dec. 31, 2016
Common stock value issued
Young Agreement [Member]
Cost of patent				$ 1,372,000
Percentage of royalty payment				1.00%
Smith Agreement [Member]
Number of shares acquired in exchange for common stock	1,000,000		300,000
Acquisition value	$ 270,000		$ 2,880,384
Fair market value acquired			2,715,000
Payments to acquire patents			165,384
Smith Agreement [Member] | Initial License Fee [Member]
Payments to acquire patents			100,000
Smith Agreement [Member] | Expenses [Member]
Payments to acquire patents			$ 65,384
Shan Agreement [Member]
Number of shares issue upon final transfer of licenses						500,000
Number of common stock shares issued during period		500,000
TNI BioTech IP, Inc. [Member]
Number of shares acquired in exchange for common stock					20,250,000
Acquisition value					$ 98,000,000
Dr. Plotnikoff [Member]
Number of shares acquired in exchange for common stock					8,000,000
TNI IP's Management [Member]
Number of shares acquired in exchange for common stock					12,250,000
Acquisition value					$ 16,006,000
Dr. Bernard Bihari [Member] | Young Agreement [Member]
Number of shares acquired in exchange for common stock				540,000
Acquisition value				$ 972,000
Assumed liabilities				$ 400,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Jul. 21, 2017	Nov. 11, 2016	Oct. 18, 2012	Oct. 31, 2017	Oct. 31, 2013	Dec. 31, 2017	Dec. 31, 2016
Cash rental expense						$ 16,777	$ 16,041
Accrued claims	$ 24,923
Payment for services performed				$ 36,000
Complete Pharmacy and Medical Solutions, LLC [Member]
Ramp up costs, percentage						100.00%
Kacem Enterprises, Inc [Member]
Consultants interest cost and attorneys' fees		$ 21,777
AHAR Pharma [Member]
Distribution agreement, description					The Company is obligated to provide delivery of an initial supply of between 1 million and 1.5 million doses of Lodonal™ product to cover AHAR Pharma’s first-year purchase commitment.
Agreements With Hubei Qianjiang Pharmaceutical Company [Member]
Percentage of gross sales			6.00%

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	12 Months Ended
	Dec. 31, 2017USD ($)shares
Loan
Robert J Dailey [Member]
Loan	$ 373,000
Interest rate	2.00%
Paul Akin [Member]
Loan	$ 30,000
Interest rate	2.00%
Mr. Wilson [Member]
Compensation paid to related party	$ 100,000
Stock options, shares | shares	500,000
Stock options, value	$ 24,998
Mr. Wilson [Member] | Noreen Griffin [Member]
Compensation paid to related party	$ 136,158
Stock options, shares | shares	1,200,000
Stock options, value	$ 59,995

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Apr. 02, 2018	Dec. 31, 2016	Dec. 31, 2017
Common stock, shares outstanding		250,428,133	386,782,473
Loan
Issuance of common stock value raised
Subsequent Event [Member]
Common stock, shares outstanding	389,846,113
Number of warrants issued	1,000,000
warrant price	$ 0.20
warrants expire term	5 years
Loan	$ 356,000
Issuance of common stock value raised	$ 125,000

Subsequent Events - Summary of

Subsequent Events - Summary of Issued Shares (Details) - Subsequent Event [Member]	3 Months Ended
	Apr. 02, 2018shares
Issuance of common stock to employees and consultants	2,862,640
Issuance of common stock as incentive to extend a debt	200,000